Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities law
NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against AstraZ
The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against AstraZeneca PLC
11:15am, Friday, 17'th Jan 2025
LOS ANGELES, CA / ACCESS Newswire / January 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZe
NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securitie
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZenecaTo Contact Him Directly To Discuss Their Options
Investors in AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN
09:15am, Friday, 17'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 17, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, fo
AstraZeneca overhauls management of its China division, FT reports
09:12am, Friday, 17'th Jan 2025
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times reported on Friday, citing two people with direct kn
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previou
NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ast
AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AZN
05:45am, Friday, 17'th Jan 2025
NEW YORK , Jan. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINIT
AstraZeneca drug for rare blood cancer gets US regulatory green light
03:28am, Friday, 17'th Jan 2025
The US Food and Drug Administration (FDA) has approved AstraZeneca PLC's (LSE:AZN) Calquence (acalabrutinib), in combination with bendamustine and rituximab, as a first-line treatment for adults with
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / January 16, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASD
AZN Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the AstraZeneca PLC Class Action
06:26pm, Thursday, 16'th Jan 2025
SAN DIEGO , Jan. 16, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC (NASDA
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm
06:22pm, Thursday, 16'th Jan 2025
NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and Decemb
Levi & Korsinsky Notifies Shareholders of AstraZeneca PLC (AZN) of a Class Action Lawsuit and an Upcoming Deadline
06:15pm, Thursday, 16'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securitie
